AdaptHealth Corp. Completes Sale of Diabetes Health Unit to Cardinal Health
AdaptHealth Corp. (NASDAQ: AHCO) announced on July 20, 2026 that it will divest its Diabetes Health unit to Cardinal Health for $235 million in cash. The transaction is part of a broader strategy by Cardinal Health to expand its at‑Home Solutions portfolio through two tuck‑in acquisitions, including the purchase of Strive Medical for a combined value of roughly $360 million.
Strategic Rationale
AdaptHealth has historically focused on providing home‑medical equipment such as mobility aids, oxygen systems, wheelchairs, and sleep‑therapy supplies to hospitals, sleep labs, skilled‑nursing facilities, and clinics. By selling the Diabetes Health business, the company seeks to streamline its operations and concentrate on its core product lines. The unit, which serves over 225,000 patients annually, operated primarily through a centralized, mail‑order, direct‑to‑patient model delivering continuous glucose monitors and related supplies. Its sale will allow AdaptHealth to redirect capital and management resources toward expanding its home‑care offerings.
Cardinal Health, meanwhile, is reinforcing its position as a leading distributor of home‑care products. The acquisition aligns with its recent purchase of Advanced Diabetes Supply (ADS) and the integration of ADS volume onto its efficient, technology‑enabled distribution network. CEO Jason Hollar described the move as a natural extension of the company’s at‑Home Solutions growth strategy, expanding capabilities across critical therapeutic categories such as diabetes management and urology.
Financial Impact
The $235 million cash consideration represents a significant inflow for AdaptHealth. Given the company’s current market capitalization of approximately $1.49 billion and a trailing close of $10.96 per share on July 16, 2026, the transaction is expected to generate a substantial return for shareholders. Although AdaptHealth’s price‑earnings ratio is negative at ‑18.39, indicating earnings below earnings per share, the proceeds from the sale should bolster the firm’s balance sheet and potentially support future investment in its remaining product segments.
Cardinal Health anticipates that the acquisition will be accretive to non‑GAAP earnings per share within the first twelve months after closing, thanks to the anticipated synergies and the ability to onboard nearly 500,000 new customers from ADS integration. The transaction also adds Strive Medical’s network, which serves over 20,000 patients annually in urology, wound care, ostomy, and incontinence supplies, further strengthening the company’s enterprise‑wide capabilities.
Operational Considerations
Both agreements are subject to customary closing conditions, including regulatory approvals. Cardinal Health has engaged legal advisors Skadden, Arps, Slate, Meagher & Flom LLP and DLA Piper for the diabetes unit acquisition, while BakerHostetler LLP and DLA Piper LLP are advising on the Strive Medical transaction. J.P. Morgan Securities LLC serves as the financial advisor for Cardinal Health on both deals.
The integration of the Diabetes Health business into Cardinal Health’s at‑Home Solutions platform is expected to leverage the company’s existing infrastructure, including the ContinuCare Pathway—a pharmacy‑to‑supplier digital referral program. By migrating all ADS volume onto its network and onboarding a substantial customer base, Cardinal Health aims to accelerate the delivery of high‑quality, technology‑enabled care in the home.
Market Implications
For AdaptHealth, the divestiture marks a pivotal shift toward consolidating its core competencies in home‑care equipment while monetizing a high‑growth business segment. For Cardinal Health, the acquisitions represent a strategic push into home‑care and direct‑to‑patient markets, positioning the company to benefit from the growing demand for remote health management solutions. As the healthcare landscape continues to evolve, the transaction underscores the importance of agile portfolio management and the pursuit of synergistic opportunities across complementary therapeutic areas.
